Ameritox names Peter Crayton senior vice president of sales

July 18, 2011

BALTIMORE, Md. – July 18, 2011 – Ameritox, the nation’s leader in pain medication monitoring, has named Peter J. Crayton its senior vice president of sales.

Crayton brings more than two decades of experience of sales leadership in the health care field to Ameritox, which provides physicians with the patented Rx GuardianSM with Rx Guardian CDSM process to help clinicians assess their chronic pain patients for adherence to their medications.

Most recently, Crayton led a team of more than 600 sales professionals for Sanofi-Aventis Pharmaceuticals, with responsibility for brands in their cardiology and metabolism portfolio.

“Pete’s leadership style impressed us,” said Ameritox CEO Ancelmo Lopes. “He is not only committed to excellence and results, but also is known as an engaged leader who makes it his business to help everyone who works for him achieve success.”

Prior to serving as area vice president for Sanofi-Aventis, Crayton was vice president of sales for its metabolism business, a role that he had worked up to after successfully leading several other product and sales efforts at the company. He has a bachelor’s degree in management/marketing from Purdue University and has also completed a health leadership program at Kellogg Graduate School and a strategic marketing program at Columbia Graduate School.

Crayton said he is excited to join Ameritox, which offers a solution to the country’s emerging difficulty in dealing with opioid use and abuse.

“The importance of pain medication monitoring is becoming abundantly clear, and I am excited to join Ameritox, the leader in this field,” Crayton said.

“We will continue to meet the needs of our physician customers better than any competitor in the marketplace,” he said, “and we will do that while running our business with the highest ethical standards.”

About Ameritox
Ameritox is the nation’s leader in pain medication monitoring solutions, offering specialized laboratory testing and reporting services. Ameritox’s expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers the most thorough pain medication monitoring lab process — Rx GuardianSMwith Rx Guardian CDSM, the only pain medication monitoring solution with a proprietary normalization algorithm and a reference database of pain patients clinically assessed for medication adherence. Patient results are compared against this database, helping physicians assess whether patients are taking their pain medications correctly. Medication monitoring through urine drug testing helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at, on Twitter @Ameritox, or on Facebook at